Group Members
Dr Shelby Barnett
Research Associate
- Email: shelby.barnett@ncl.ac.uk
- Address: Newcastle University Centre for Cancer
Translational and Clinical Research Institute
Paul O'Gorman Building
Medical School
Framlington Place
Newcastle upon Tyne
NE2 4HH
Background
Qualifications
BSc (Hons) Biomedical Science (Pharmacology), University of Aberdeen
PhD (Pharmacokinetics), Manchester University
Membership
International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)
British Pharmacological Society (BPS)
The British Association for Cancer Research (BACR)
Children’s Cancer and Leukaemia Group (CCLG)
Research
I am currently a Research Associate at Newcastle University within the Centre for Cancer. My main focus of research is in the area of paediatric clinical pharmacology. Primarily investigating the pharmacokinetics of chemotherapeutics used to treat challenging paediatric patient populations, such as neonates and infants.
Research Interests
- Paediatric Pharmacokinetics/ Clinical Pharmacology
- Therapeutic Drug Monitoring (TDM)
- Drug-Drug Interactions (DDIs)
- Endogenous biomarkers for DDI prediction
- Micro-sampling techniques
Publications
- Nijstad AL, Barnett S, Lalmohamed A, Bérénos IM, Parke E, Carruthers V, Tweddle DA, Kong J, Zwaan CM, Huitema ADR, Veal GJ. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. European Journal of Cancer 2022, 164, 137-154.
- Barnett S, Hellman F, Parke E, Makin G, Tweddle DA, Osborne C, Hempel G, Veal GJ. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. European Journal of Cancer 2022, 164, 127-136.
- Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population. Pharmaceuticals 2021, 14(3), 272.
- Takita H, Barnett S, Zhang Y, Ménochet M, Shen H, Ogungbenro K, Galetin A. PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability. CPT: Pharmacometrics & Systems Pharmacology 2021, 10(2), 137-147.
- Barnett S, Kong J, Makin G, Veal GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. British Journal of Clinical Pharmacology 2021, 87(2), 256-262.
- Barnett S, Ogungbenro K, Ménochet K, Shen H, Lai Y, Humphreys WG, Galetin A. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology & Therapeutics 2018, 104(3), 564-574.
- Barnett S, Ogungbenro K, Menochet K, Shen H, Humphreys GW, Galetin A. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. Journal of Pharmacology and Experimental Therapeutics 2019, 368(1), 125-135.
- Beedie SL, Rore HM, Barnett S, Chau CH, Luo W, Greig NH, Figg WD, Vargesson N. In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget 2016, 7(22), 33237-33245.
- Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD. Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues. Molecular Cancer Therapeutics 2015, 14(10), 2228-2237.